Loading…
ProMIS Neurosciences, Inc. is projected to rise to $13.94 by 2027, a +2% move from its current price of $13.72. PMN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $12.89 | $13.72 | $14.61 | +0.02% |
| Aug 5 | $12.56 | $13.73 | $15.00 | +0.04% |
| Aug 6 | $12.31 | $13.73 | $15.31 | +0.06% |
| Aug 7 | $12.11 | $13.73 | $15.57 | +0.08% |
| Aug 8 | $11.93 | $13.73 | $15.81 | +0.10% |
| Aug 9 | $11.78 | $13.74 | $16.02 | +0.12% |
| Aug 10 | $11.63 | $13.74 | $16.22 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.63 | $13.74 | $16.22 | +0.13% |
| Week 2 | $10.87 | $13.76 | $17.41 | +0.27% |
| Week 3 | $10.33 | $13.78 | $18.37 | +0.40% |
| Week 4 | $9.89 | $13.79 | $19.24 | +0.54% |
| Week 5 | $9.52 | $13.81 | $20.04 | +0.67% |
| Week 6 | $9.20 | $13.83 | $20.79 | +0.81% |
| Week 7 | $8.92 | $13.85 | $21.51 | +0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Its proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
Lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences is headquartered in Toronto, Canada.
PMN is the publicly traded company ProMIS Neurosciences, Inc. (symbol PMN) with a current price of $14.52 and a market capitalization of $130.21M, ranking 3886 by market cap. The stock sits within a 30-day trading window and has a price near-term context that investors monitor alongside its technicals.
Current price: $14.52; Market cap: $130.21M; Rank: 3886.
The near-term setup shows the stock trading within a 30-day range of $10.34 to $20.39, with a current price near the middle of that corridor. The 30-day picture is supported by a neutral sentiment with RSI14 at 40, and moving averages at SMA50 $11.56 and SMA200 $11.96, with a defined support at $10.05 and resistance at $15.19.
A major floor 41.0% below — a decisive break under it would weaken the trend.
The nearest floor, 25.4% below — buyers have tended to step in here.
The nearest ceiling, 10.7% above — a clean break opens room to run.
A major ceiling 31.2% above — clearing it would confirm fresh momentum.
Key PMN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.79 | Sell | $13.92 | Sell |
| MA 10 | $13.73 | Sell | $13.77 | Sell |
| MA 20 | $13.79 | Sell | $13.43 | Buy |
| MA 50 | $11.90 | Buy | $12.66 | Buy |
| MA 100 | $12.55 | Buy | $12.49 | Buy |
| MA 200 | $11.98 | Buy | $13.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.83 | Neutral |
| Stoch RSI (14) | 39.37 | Neutral |
| CCI (20) | -6.94 | Neutral |
| Williams %R (14) | -42.36 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -2.07 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 57.64 | Neutral |
| TRIX (15) | 0.76 | Buy |
| Awesome (5,34) | 1.13 | Buy |
| Ultimate (7,14,28) | 51.16 | Neutral |
| Momentum (10) | -1.47 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 14.60 | Sell |
| ADX (14) | 20.55 | Buy |
| ATR (14) | 0.76 | Info |
Technical snapshot for the last 30 days shows sentiment is NEUTRAL. RSI14 is 40, with the SMA50 at $11.56 and the SMA200 at $11.96, illustrating a cautious posture in the mid-range. The immediate support is $10.05 and the resistance is $15.19.
The thirty-day range spans from $10.34 to $20.39, placing the current price of $14.52 within that corridor and suggesting a range-bound atmosphere in the near term. The volatility backdrop is reflected in the annualized volatility metric of 100, underscoring the variability seen in this period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.14 | $13.72 | $18.32 | 0% | Neutral | |
| $10.16 | $13.94 | $20.68 | +2% | Neutral | |
| $8.23 | $12.02 | $19.02 | -12% | Neutral | |
| $7.60 | $11.69 | $19.43 | -15% | Neutral | |
| $7.43 | $11.99 | $20.76 | -13% | Neutral | |
| $8.93 | $15.05 | $26.99 | +10% | Neutral | |
| $10.28 | $18.08 | $33.43 | +32% | Bullish | |
| $9.52 | $17.44 | $33.16 | +27% | Bullish | |
| $9.69 | $18.47 | $36.01 | +35% | Bullish | |
| $8.27 | $16.38 | $32.67 | +19% | Neutral | |
| $11.43 | $25.41 | $55.72 | +85% | Bullish | |
| $21.95 | $48.77 | $112.18 | +255% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.14 | $13.72 | $16.55 | +0.00% |
| September 2026 | $10.81 | $13.14 | $16.68 | -4.21% |
| October 2026 | $11.32 | $13.96 | $18.08 | +6.24% |
| November 2026 | $11.52 | $14.36 | $18.90 | +2.88% |
| December 2026 | $10.89 | $13.73 | $18.32 | -4.44% |
Click any year to see its month-by-month PMN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ProMIS Neurosciences, Inc.'s 2026 outlook centres on $13.72, within a $7.14 to $18.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PMN could reach as high as $20.68, with a base case around $13.94 and support toward $10.16 — roughly +2% from $13.72. A consolidation phase looks the most probable path here.
Expect PMN to range from $8.23 to $19.02 through 2028. The $12.02 average target implies a -12% move from current prices. That is -14% versus the projected 2027 average. Price action looks broadly range-bound.
The PMN price prediction for 2029 points to an average of $11.69 (low $7.60, high $19.43) — a potential decline of -15% on today's $13.72. A consolidation phase looks the most probable path here.
In 2030, PMN is projected to trade between $7.43 and $20.76, averaging $11.99 — a potential decline of -13% from today's $13.72. That is up +3% on the projected 2029 average. Price action looks broadly range-bound.
ProMIS Neurosciences, Inc.'s 2031 outlook centres on $15.05, within a $8.93 to $26.99 range. That is up +26% on the projected 2030 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, PMN could reach as high as $33.43, with a base case around $18.08 and support toward $10.28 — roughly +32% from $13.72. Momentum favours further upside here.
Expect PMN to range from $9.52 to $33.16 through 2033. The $17.44 average target implies a +27% move from current prices. That is -4% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The PMN price prediction for 2034 points to an average of $18.47 (low $9.69, high $36.01) — a potential gain of +35% on today's $13.72. Momentum favours further upside here.
In 2035, PMN is projected to trade between $8.27 and $32.67, averaging $16.38 — a potential gain of +19% from today's $13.72. That is -11% versus the projected 2034 average. A consolidation phase looks the most probable path here.
ProMIS Neurosciences, Inc.'s 2040 outlook centres on $25.41, within a $11.43 to $55.72 range. That is up +55% on the projected 2035 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2050, PMN could reach as high as $112.18, with a base case around $48.77 and support toward $21.95 — roughly +255% from $13.72. Buyers look set to stay in control over this stretch.
Investing $1,000 in PMN today (≈ 72.886297 PMN) could be worth
$3,554.94
+$2,554.94 (+255%) by 2050 · US Dollar
Based on the average projected PMN price of $48.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMNwould be worth at today's price.
$1,000 invested in PMN on Jul 31, 2025 (≈ 51.948052 PMN) would be worth
$712.73
-$287.27 (-28.7%) today · 0.71× · US Dollar
Based on a PMN entry price of $19.25 vs. today's $13.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.2 | $1,124.59 | +12.5% |
| 1 month ago | $13.45 | $1,020.07 | +2.0% |
| 3 months ago | $11.01 | $1,246.14 | +24.6% |
| 6 months ago | $14.05 | $976.51 | -2.3% |
| 1 year ago | $19.25 | $712.73 | -28.7% |
| All time (5.0y) ago | $270 | $50.81 | -94.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMN forecast.
Our base-case forecast reaches $27.00 around 2050.
Implied market cap at $27.00: $242.13M
The multi-year forecast presents a mixed but progressively bullish longer-term path. In 2026, the average is $14.52 with a 0% ROI and a NEUTRAL sentiment. By 2027, the average increases to $15.17 with a 4.5% ROI and NEUTRAL sentiment, and in 2028 the average is $13.00 with a -10.5% ROI.
For 2029, the average is $12.49 with a -14% ROI, and 2030 shows an average of $12.54 with a -13.7% ROI, all with NEUTRAL sentiment. The forecast turns modestly more positive in 2032, where the average rises to $17.44 with a 20.1% ROI and a BULLISH sentiment, followed by 2033 at $17.60 with a 21.2% ROI and BULLISH sentiment, and 2034 at $18.19 with a 25.3% ROI and BULLISH sentiment.
Looking further out, 2040 shows a substantial leap to an average of $24.04 with a 65.5% ROI and BULLISH sentiment, and 2050 projects an average of $42.58 with a 193.2% ROI and BULLISH sentiment. These figures represent estimates, not guarantees, and are subject to the risks inherent in clinical-stage biotechnology and market conditions.
Tap a question to reveal the answer.
Min $7.88; Avg $12.54; Max $21.47; ROI -13.7%; Sentiment NEUTRAL.
The 2050 forecast lists a max of $97.93, with an average of $42.58 and a 193.2% ROI, indicating the possibility to exceed $50 within the horizon.
Min $11.12; Avg $15.17; Max $22.36; ROI 4.5%; Sentiment NEUTRAL.
Min $10.82; Avg $24.04; Max $51.85; ROI 65.5%; Sentiment BULLISH.
Current price $14.52; Market cap $130.21M.
ProMIS Neurosciences, Inc. Community Discussion
0Share your ProMIS Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.